01—Abstract
Summary
Summary of the 8-K filed August 6, 2025. Cited figures are marked; the original filing is the authoritative source.
BeOne Medicines (ONC) reported strong second-quarter 2025 results, with total revenue rising 42% year over year to $1.32 billiona ($1.315 billion).
Growth was driven by BRUKINSA, whose global revenue increased 49% to $950 millionb, including U.S. sales of $684 million (up 43%) and European sales of $150 million (up 85%). TEVIMBRA sales grew 22% to $194 million. Gross margin on product sales expanded to 87.4% on a GAAP basis from 85.0%, reflecting a higher mix of BRUKINSA and cost-of-sales productivity gains.
The company swung to GAAP operating income of $88 millionc from a $107 million loss a year earlier, and reported GAAP net income of $94 million, or $0.84 per diluted ADS. Non-GAAP diluted EPS per ADS was $2.25, and free cash flow was $220 million. Operating expenses grew more slowly than revenue.
GAAP operating expenses rose 18% to $1.06 billiond, with SG&A up 21% on commercial expansion in the U.S. and Europe and R&D up 15%. SG&A fell to 41% of product sales from 48%, which drove most of the operating leverage. The balance sheet strengthened, with cash, cash equivalents and restricted cash of $2.79 billion against debt of $954 million at June 30, 2025.
Management raised the low end of its FY2025 total revenue guidance to $5.0–5.3 billion from $4.9–5.3 billion, kept GAAP operating expense guidance at $4.1–4.4 billion, and moved its gross margin outlook to the mid-to-high 80% range. It continues to expect positive GAAP operating income and positive free cash flow for the full year.
The main watch items are the sustainability of BRUKINSA's growth against a competitive BTKi class, the pace of pipeline execution (sonrotoclax and BGB-16673 Phase 3 readouts and trial starts are expected in 2H 2025), and the gap between GAAP and non-GAAP results, which is largely driven by share-based compensation. Investors should also note that the filing furnishes the earnings press release under Item 2.02 rather than filing it, and that the guidance is based on forward-looking assumptions that carry significant uncertainty.
02—Key points
Key Highlights
- Total revenue grew 42% year over year to $1.315 billion, with product revenue up 41% to $1.302 billion.
- Global BRUKINSA revenue rose 49% to $950 million, led by U.S. sales of $684 million (+43%) and European sales of $150 million (+85%).
- GAAP operating income swung to $88 million from a $107 million loss, and GAAP diluted EPS was $0.84 per ADS versus a $1.15 loss a year earlier.
- Non-GAAP diluted EPS per ADS was $2.25 and free cash flow was $220 million, compared with a $206 million outflow in Q2 2024.
- SG&A as a share of product sales fell to 41% from 48%, while gross margin on product sales improved to 87.4% (GAAP) from 85.0%.
- FY2025 total revenue guidance was narrowed to $5.0–5.3 billion from $4.9–5.3 billion; GAAP operating expense guidance of $4.1–4.4 billion was maintained.
- The balance sheet held $2.79 billion of cash and restricted cash against $954 million of debt, and management expects 20+ R&D milestones over the next 18 months.
03—Questions
Frequently Asked Questions
What drove the 42% increase in total revenue?
Growth was driven mainly by BRUKINSA, whose global sales rose 49% to $950 million. U.S. BRUKINSA sales grew 43% on strong demand across all indications, with a modest benefit from net pricing, and European sales grew 85% on higher market share in major markets. TEVIMBRA sales rose 22% to $194 million, and in-licensed products from Amgen also contributed.
Is the company now profitable, and how does GAAP compare with non-GAAP results?
On a GAAP basis, the company reported Q2 2025 operating income of $88 million and net income of $94 million, or $0.84 per diluted ADS. Non-GAAP results were higher, with adjusted operating income of $275 million and adjusted diluted EPS of $2.25 per ADS. The gap is mainly share-based compensation of $151 million in the quarter, plus depreciation and amortization. Investors should weigh GAAP results most heavily, since share-based compensation is a real, recurring cost.
Did the company change its full-year 2025 outlook?
It raised the bottom of its total revenue guidance to $5.0–5.3 billion from $4.9–5.3 billion. It kept GAAP operating expenses at $4.1–4.4 billion and continues to expect positive GAAP operating income and positive free cash flow for FY2025. Gross margin guidance moved to the mid-to-high 80% range from the mid-80% range. The guidance excludes any new material business development activity or unusual items.
How strong is the company's cash position and cash generation?
Cash, cash equivalents and restricted cash were $2.79 billion at June 30, 2025, up from $2.64 billion at year-end 2024. Operating cash flow was $264 million in Q2 2025, and free cash flow was $220 million after $44 million of capital expenditures. Total debt was $954 million, down from $1.02 billion at December 31, 2024. Management expects positive free cash flow for FY2025.
What are the key catalysts and risks to watch in the next several quarters?
Near-term catalysts include the interim analysis of the Phase 3 MANGROVE trial for BRUKINSA in treatment-naive mantle cell lymphoma, the data readout for sonrotoclax in relapsed/refractory MCL, the Phase 3 readout for zanidatamab in first-line HER2-positive gastroesophageal adenocarcinoma, and the start of the BGB-16673 Phase 3 trial against pirtobrutinib, all expected in 2H 2025. Key risks include the competitive BTK inhibitor market, the reliance on BRUKINSA for most revenue, clinical and regulatory outcomes, and the company's ability to sustain profitability as it invests in commercial expansion.
04—Continue